The pharmaceutical industry has faced declining research and development (R&D) productivity for decades. During the early 2010s, Pfizer saw its R&D productivity drop even more sharply than did its industry peers. As impactful medicines the company had developed and brought to patients in previous years lost exclusivity, Pfizer faced a steep patent cliff with a cumulative revenue impact of >US$28 billion through 2018. Since 2010, the company has embarked on a focused turnaround effort to improve R&D productivity. Although some efforts will need more time to prove themselves, there are early signs of a turnaround now, particularly in terms of Phase II success rates. Here, we share some learnings from a decade of experience as one of the largest R&D organizations in the industry.

几十年来，制药行业一直面临着研发 (R&D) 生产力下降的问题。在 2010 年代初期，辉瑞的研发生产力下降幅度甚至超过了同行。由于公司前几年开发并带给患者的有影响力的药物失去了独占权，辉瑞面临着陡峭的专利悬崖，到 2018 年的累计收入影响超过 280 亿美元。自 2010 年以来，该公司开始专注于扭转局面，以改善研发生产力。尽管有些努力需要更多时间来证明自己，但现在已经有了好转的早期迹象，尤其是在第二阶段的成功率方面。在这里，我们分享了作为业内最大的研发组织之一的十年经验的一些经验教训。